Senti Biosciences (NASDAQ:SNTI – Get Free Report) announced its earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.13) by $2.46, Zacks reports. The firm had revenue of $5.86 million during the quarter, compared to the consensus estimate of $2.80 million.
Senti Biosciences Stock Down 3.0 %
SNTI stock opened at $3.51 on Friday. Senti Biosciences has a twelve month low of $1.52 and a twelve month high of $16.94. The firm has a market cap of $16.95 million, a PE ratio of -0.23 and a beta of 2.52. The business has a 50 day moving average of $3.94 and a 200 day moving average of $3.44.
Analyst Upgrades and Downgrades
Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Senti Biosciences in a research report on Monday, December 2nd.
Senti Biosciences Company Profile
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
See Also
- Five stocks we like better than Senti Biosciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
- Buy P&G Now, Before It Sets A New All-Time High
- Lucid’s Stock Comeback—Is a Long-Term Recovery Ahead?
- What is the Shanghai Stock Exchange Composite Index?
- BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
